- Home
- NTRA vs DKNG Comparison
NTRA vs DKNG Comparison
Compare NTRA & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- DKNG
- Stock Information
- Founded
- NTRA 2003
- DKNG 2012
- Country
- NTRA United States
- DKNG United States
- Employees
- NTRA N/A
- DKNG N/A
- Industry
- NTRA Medical Specialities
- DKNG Services-Misc. Amusement & Recreation
- Sector
- NTRA Health Care
- DKNG Consumer Discretionary
- Exchange
- NTRA Nasdaq
- DKNG Nasdaq
- Market Cap
- NTRA 22.1B
- DKNG 18.3B
- IPO Year
- NTRA 2015
- DKNG N/A
- Fundamental
- Price
- NTRA $167.46
- DKNG $41.51
- Analyst Decision
- NTRA Strong Buy
- DKNG Strong Buy
- Analyst Count
- NTRA 16
- DKNG 25
- Target Price
- NTRA $160.63
- DKNG $50.80
- AVG Volume (30 Days)
- NTRA 1.2M
- DKNG 8.1M
- Earning Date
- NTRA 02-26-2025
- DKNG 02-13-2025
- Dividend Yield
- NTRA N/A
- DKNG N/A
- EPS Growth
- NTRA N/A
- DKNG N/A
- EPS
- NTRA N/A
- DKNG N/A
- Revenue
- NTRA $1,531,955,000.00
- DKNG $4,605,784,000.00
- Revenue This Year
- NTRA $54.35
- DKNG $36.44
- Revenue Next Year
- NTRA $10.17
- DKNG $30.29
- P/E Ratio
- NTRA N/A
- DKNG N/A
- Revenue Growth
- NTRA 54.94
- DKNG 40.01
- 52 Week Low
- NTRA $62.96
- DKNG $28.69
- 52 Week High
- NTRA $183.00
- DKNG $49.57
- Technical
- Relative Strength Index (RSI)
- NTRA 52.44
- DKNG 59.69
- Support Level
- NTRA $163.42
- DKNG $38.61
- Resistance Level
- NTRA $174.15
- DKNG $41.76
- Average True Range (ATR)
- NTRA 8.16
- DKNG 1.54
- MACD
- NTRA -0.75
- DKNG 0.41
- Stochastic Oscillator
- NTRA 44.26
- DKNG 95.77
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in about 30 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.